TRIDENT post-hoc analysis of low-dose triple combination therapy by kidney function in people with prior intracerebral hemorrhage presented at American Heart Association’s Scientific Sessions 2026

A post-hoc analysis of the TRIDENT trial indicates that the low-dose combination therapy GMRx2 effectively reduces the risk of recurrent stroke in patients with prior intracerebral hemorrhage. The benefits were found to be consistent across different levels of kidney function.
Why it matters
This study provides clinical evidence for managing blood pressure in high-risk stroke patients, particularly those with chronic kidney disease.
Blood pressure (BP) reduction is the only route of therapy with the demonstrated potential to prevent intracerebral hemorrhage (ICH) 1,2. However, the benefits of intensive BP-lowering and the optimal approach to treatment are uncertain. People with chronic kidney disease (CKD) are at twice the risk of stroke events compared to people with normal kidney function. This post-hoc analysis from the TRIDENT trial examined the effects of GMRx2, George Medicines’ single pill low dose combination therapy of telmisartan 20 mg, amlodipine 2.5 mg, indapamide 1.25 mg, on the risk of recurrent stroke and serious adverse events (SAEs) by kidney function. TRIDENT randomized 1,670 adults with prior ICH and systolic blood pressure (SBP) of 130-160 mmHg to GMRx2 or matching placebo, both in addition to usual care.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in